AARD_OUT_1 [2025-04-04 05:38:50 -0400] 3073 Bytes | 833 tokens | Cum: 833 tkns (10.41% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Aardvark Therapeutics (AARD) which is at 11 up from 8.69. So, I pulled together a bunch of data for you to look over real fast. It's still early, 5:38:49 AM on Fri Apr 04, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: Aardvark Therapeutics (AARD)
IPO: 2025-02-13 (1 Month Ago)
Market Cap: $177,276,485
Shares Outstanding: 21,380,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Here’s the first list of news for Aardvark Therapeutics:

C1 - Mar-31-25 04:10PM - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights
C2 - Mar-27-25 04:18PM - Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower
C3 - Mar-21-25 09:20AM - Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
C4 - Mar-14-25 11:25AM - Aardvark Therapeutics, Inc. Common Stock (AARD): Among Top Insider Purchases Last Month
C5 - Mar-03-25 02:55PM - Aardvark Therapeutics (AARD): Among Stocks With At Least $10 Million In Insider Spending Recently
C6 - Feb-12-25 10:38PM - Aardvark Therapeutics Announces Pricing of Initial Public Offering

Prior AI Reports for AARD:
1. 2025-04-01 – Score: 50 – Target: 9.0400 – Highs: 9.7000 / 9.4200 / 9.19
mixed-signals-declining-performance-amid-insider-trading-activity

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Aardvark Therapeutics (AARD).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

AARD_OUT_3 [2025-04-04 05:38:53 -0400] 1100 Bytes | 318 tokens | Cum: 1154 tkns (14.42% of 8k)
==========================================================================

Showing C1 (chunk 1 of 6): C1:
**Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights**
Date: Mar-31-25 04:10PM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/03/31/3052780/0/en/Aardvark-Therapeutics-Reports-Full-Year-2024-Financial-Results-and-Provides-Business-Highlights.html

March 31, 2025 16:10 ET| Source:Aardvark Therapeutics, Inc.Aardvark Therapeutics, Inc.

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today reported financial results for the full year ended December 31, 2024, and provided business highlights.

“Appetite represents a reward-based neurological drive and hunger represents a penalty or p

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_5 [2025-04-04 05:38:54 -0400] 997 Bytes | 282 tokens | Cum: 1512 tkns (18.90% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T16:00:29Z - Aardvark Therapeutics (NASDAQ:AARD) Earns "Outperform" Rating from Royal Bank of Canada...
A2 - 2025-04-02T15:39:15Z - Aardvark Therapeutics' (AARD) "Overweight" Rating Reiterated at Cantor Fitzgerald...
A3 - 2025-03-31T20:10:33Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights...
A4 - 2025-03-31T20:34:29Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights...
A5 - 2025-03-31T20:25:51Z - Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights | Ta...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

AARD_OUT_7 [2025-04-04 05:38:58 -0400] 1098 Bytes | 312 tokens | Cum: 1826 tkns (22.82% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Aardvark Therapeutics (NASDAQ:AARD) Earns "Outperform" Rating from Royal Bank of Canada**Date: 2025-04-03Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/aardvark-therapeutics-nasdaqaard-earns-outperform-rating-from-royal-bank-of-canada-2025-04-01/Aardvark Therapeutics (NASDAQ:AARD - Get Free Report)'s stock had its "outperform" rating reissued by analysts at Royal Bank of Canada in a note issued to investors on Tuesday,Benzinga reports. They currently have a $21.00 price objective on the stock. Royal Bank of Canada's price objective points to a potential upside of 167.52% from the stock's current price.

AARD has been the topic of several other reports. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $50.00 price target on shares of Aardvark Therapeutics in a research note on Tuesday. Morga

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_9 [2025-04-04 05:38:59 -0400] 407 Bytes | 106 tokens | Cum: 2018 tkns (25.22% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-02-21T18:00:00Z - Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AARD_OUT_11 [2025-04-04 05:39:02 -0400] 913 Bytes | 237 tokens | Cum: 2257 tkns (28.21% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/21/3030614/0/en/Evolving-Landscape-of-Obesity-Key-Market-Insights-of-Latest-Published-Different-Types-of-Obesity-DelveInsight.htmlThe obesity market is projected to grow from 2024 to 2034 due to the rising prevalence of obesity and the extensive pipeline of emerging drugs with improved safety profiles. The article discusses different types of obesity, including hypothalamic, pediatric, POMC deficiency, and syndromic/monogenic obesity, and the current treatment landscape and pipeline for each.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_13 [2025-04-04 05:39:04 -0400] 1070 Bytes | 257 tokens | Cum: 2591 tkns (32.39% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and related notes ...

S2 - 2025-03-31 8-K Item 2.02 Results of Oper and Fin Cond.

On March 31, 2025, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the year ended December 31, 2024 and providing a business update. The full text of the press release is furnished a...

S3 - 2025-03-31 10-K It em 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the CONS financial statements and related notes ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

AARD_OUT_15 [2025-04-04 05:39:05 -0400] 1098 Bytes | 231 tokens | Cum: 2824 tkns (35.30% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
It em 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes thereto included elsewhere in this Annual Report. This discussion and other parts of this Annual Report contain forward-looking statements that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under Part I, Item 1A, Risk Factors, of this Annual Report and elsewhere in this Annual Report. You should carefully read Part I, Item 1A,

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

AARD_OUT_17 [2025-04-04 05:39:15 -0400] 5614 Bytes | 1500 tokens | Cum: 4326 tkns (54.07% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 149,250 | Perf Month: -23.64% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 190.58K | Perf Quarter: - | Short Float: 2.68% | ROE: - |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.78 | Index: - | Short Ratio: 1.74 | ROI: - |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 41.26 | Market Cap: 188.54M | Short Interest: 0.33M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 1.53 | Shs Outstand: 21.70M | Beta: - | EPS Surprise: 39.02% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -7.07% | Shs Float: 12.39M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -21.13% | Inst Own: 10.05% | Sales past 5Y: 0.00% | Earnings: Mar 31 AMC |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -21.13% | Insider Own: 42.89% | Employees: 22 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: -2.36% | Insider Trans: 18.67% | Debt/Eq: - | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Cormorant Asset Management, LP (Unknown Title) on 2025-02-14
- Common Stock: 800189 shares at $N/A (I)
- Common Stock: 187500 shares at $16 (I)
- Series C Convertible Preferred Stock: 6780810 shares at $N/A (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Sun Nelson (Chief Financial Officer) on 2025-02-14
- Common Stock: 7001 shares at $N/A (D)
- Common Stock: 10000 shares at $16 (D)
- Series C Convertible Preferred Stock: 59332 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Lee Tien-Li (Chief Executive Officer) on 2025-02-14
- Common Stock: 41303 shares at $N/A (D)
- Common Stock: 16542 shares at $16 (D)
- Series A Convertible Preferred Stock: 350002 shares at $0 (D)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Vickers Venture Fund VI Pte Ltd (Unknown Title) on 2025-02-14
- Common Stock: 1637411 shares at $N/A (I)
- Common Stock: 413491 shares at $N/A (I)
- Series A Convertible Preferred Stock: 13875429 shares at $0 (I)
- Series B Convertible Preferred Stock: 3503919 shares at $0 (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Chi Jeffrey (Unknown Title) on 2025-02-14
- Common Stock: 133364 shares at $N/A (I)
- Series C Convertible Preferred Stock: 1130135 shares at $0 (I)

Inside Trans: Aardvark Therapeutics, Inc. (AARD) by Decheng Capital Global Life Sciences Fund IV, L.P. (Unknown Title) on 2025-02-14
- Common Stock: 2333887 shares at $N/A (I)
- Common Stock: 333412 shares at $N/A (I)
- Common Stock: 625000 shares at $16 (I)
- Common Stock: 625000 shares at $16 (I)
- Series C Convertible Preferred Stock: 19777363 shares at $0 (I)
- Series C Convertible Preferred Stock: 2825337 shares at $0 (I)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: N/A
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.69
Average Volume: 132618.77
30-Day High: 11.38
30-Day Low: 7.51
No detailed financial data available.
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

AARD_OUT_19 [2025-04-04 05:39:17 -0400] 687 Bytes | 169 tokens | Cum: 4754 tkns (59.42% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

AARD_IN_21 [2025-04-04 05:39:17 -0400] 126 Bytes | 29 tokens | Cum: 4813 tkns (60.16% of 8k)
==========================================================================

====================================
[2025-04-04 05:39:17] # Analysis Completed
Elapsed Time: 28.14 seconds